Non-viral factors contributing to hepatocellular carcinoma

World Journal of Hepatology

Volumn 5, Issue 6, 2013, Pages 311-322

  Hamed, Manal A ^a   Ali, Sanaa A ^a  

^a NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

Hepatocellular carcinoma; Non viral factors; Viral etiologic factors

Indexed keywords

EID: 84880767971     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v5.i6.311     Document Type: Article

References (103)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108 [PMID: 15761078 DOI: 10.3322/canjclin.55.2.74]
2. El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 2002; 35: S72-S78 [PMID: 12394209 DOI: 10.1097/00004836-200211002-00002]
3. Thomas MB, Zhu AX. Hepatocellular carcinoma: the need for progress. J Clin Oncol 2005; 23: 2892-2899 [PMID: 15860847 DOI: 10.1200/JCO.2005.03.196]
4. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576 [PMID: 17570226 DOI: 10.1053/j.gastro.2007.04.061]
5. Poustchi H, Sepanlou SG, Esmaili1 S, Mehrabi N, Ansarymoghadam A. Hepatocellular carcinoma in the world and the Middle East. Middle East J Diges Dis 2010; 2: 31-41
6. Kirk GD, Bah E, Montesano R. Molecular epidemiology of human liver cancer: insights into etiology, pathogenesis and prevention from The Gambia, West Africa. Carcinogenesis 2006; 27: 2070-2082 [PMID: 16679307 DOI: 10.1093/carcin/bgl060]
7. Addario L, Tritto G, Cavaglià E, Amodio F, Giannelli E, Di Costanzo GG. Preserved liver function, portal thrombosis and absence of oesophageal varices are risk factors for metastasis of hepatocellular carcinoma. Dig Liver Dis 2011; 43: 319-324 [PMID: 20952262 DOI: 10.1016/j.dld.2010.09.003]
8. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-750 [PMID: 10072408 DOI: 10.1056/NEJM199903113401001]
9. Hassan MM, Spitz MR, Thomas MB, Curley SA, Patt YZ, Vauthey JN, Glover KY, Kaseb A, Lozano RD, El-Deeb AS, Nguyen NT, Wei SH, Chan W, Abbruzzese JL, Li D. The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States. J Hepatol 2009; 50: 334-341 [PMID: 19070394 DOI: 10.1016/j.jhep.2008.08.016]
10. Anwar WA, Khaled HM, Amra HA, El-Nezami H, Loffredo CA. Changing pattern of hepatocellular carcinoma (HCC) and its risk factors in Egypt: possibilities for prevention. Mutat Res 2008; 659: 176-184 [PMID: 18346933 DOI: 10.1016/j.mrrev.2008.01.005]
11. Rahman El-Zayadi A, Abaza H, Shawky S, Mohamed MK, Selim OE, Badran HM. Prevalence and epidemiological features of hepatocellular carcinoma in Egypt-a single center experience. Hepatol Res 2001; 19: 170-179 [PMID: 11164741 DOI: 10.1016/S1386-6346(00)00105-4]
12. El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 2000; 160: 3227-3230 [PMID: 11088082 DOI: 10.1001/archinte.160.21.3227]
13. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625-1638 [PMID: 12711737 DOI: 10.1056/NEJMoa021423]
14. Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol 2004; 40: 578-584 [PMID: 15030972 DOI: 10.1016/j.jhep.2004.02.013]
15. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126: 460-468 [PMID: 14762783 DOI: 10.1053/j.gastro.2003.10.065]
16. Regimbeau JM, Colombat M, Mognol P, Durand F, Abdalla E, Degott C, Degos F, Farges O, Belghiti J. Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl 2004; 10 (Suppl 1): S69-73 [PMID: 14762843]
17. James WP. The epidemiology of obesity: the size of the problem. J Intern Med 2008; 263: 336-352 [PMID: 18312311 DOI: 10.1111/j.1365-2796.2008.01922.x]
18. Blonski W, Kotlyar DS, Forde KA. Non-viral causes of hepatocellular carcinoma. World J Gastroenterol 2010; 16: 3603-3615 [PMID: 20677332 DOI: 10.3748/wjg.v16.i29.3603]
19. Kauppinen R, Mustajoki P. Acute hepatic porphyria and hepatocellular carcinoma. Br J Cancer 1988; 57: 117-120 [PMID: 2831925 DOI: 10.1038/bjc.1988.23]
20. Rudnick DA, Perlmutter DH. Alpha-1-antitrypsin deficiency: a new paradigm for hepatocellular carcinoma in genetic liver disease. Hepatology 2005; 42: 514-521 [PMID: 16044402 DOI: 10.1002/hep.20815]
21. Meza-Junco J, Montaño-Loza AJ, Martínez-Benitez B, Kimura-Hayama E. Hepatocellular carcinoma in patients with autoimmune liver diseases: two case reports and literature review. Ann Hepatol 2007; 6: 122-126 [PMID: 17519838]
22. Xu R, Hajdu CH. Wilson Disease and Hepatocellular Carcinoma. Gastroenterol Hepatol (N Y) 2008; 4: 438-439
23. Powell LW, Subramaniam VN, Yapp TR. Haemochromatosis in the new millennium. J Hepatol 2000; 32 (Suppl 1): 48-62 [PMID: 10728794]
24. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, Dormishian F, Domingo R Jr, Ellis MC, Fullan A, Hinton LM, Jones NL, Kimmel BE, Kronmal GS, Lauer P, Lee VK, Loeb DB, Mapa FA, McClelland E, Meyer NC, Mintier GA, Moeller N, Moore T, Morikan. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13: 399-408 [PMID: 8696333]
25. Elmberg M, Hultcrantz R, Ekbom A, Brandt L, Olsson S, Olsson R, Lindgren S, Lööf L, Stål P, Wallerstedt S, Almer S, Sandberg-Gertzén H, Askling J. Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology 2003; 125: 1733-1741 [PMID: 14724826 DOI: 10.1053/j.gastro.2003.09.035]
26. Yang Q, McDonnell SM, Khoury MJ, Cono J, Parrish RG. Hemochromatosis-associated mortality in the United States from 1979 to 1992: an analysis of Multiple-Cause Mortality Data. Ann Intern Med 1998; 129: 946-953 [PMID: 9867747]
27. Fracanzani AL, Conte D, Fraquelli M, Taioli E, Mattioli M, Losco A, Fargion S. Increased cancer risk in a cohort of 230 matched control patients with non-iron-related chronic liver disease. Hepatology 2001; 33: 647-651 [PMID: 11230745 DOI: 10.1053/jhep.2001.22506]
28. Mandishona E, MacPhail AP, Gordeuk VR, Kedda MA, Paterson AC, Rouault TA, Kew MC. Dietary iron overload as a risk factor for hepatocellular carcinoma in Black Africans. Hepatology 1998; 27: 1563-1566 [PMID: 9620327 DOI: 10.1002/hep.510270614]
29. Borgna-Pignatti C, Vergine G, Lombardo T, Cappellini MD, Cianciulli P, Maggio A, Renda D, Lai ME, Mandas A, Forni G, Piga A, Bisconte MG. Hepatocellular carcinoma in the thalassaemia syndromes. Br J Haematol 2004; 124: 114-117 [PMID: 14675416 DOI: 10.1046/j.1365-2141.2003.04732.x]
30. Moyo VM, Makunike R, Gangaidzo IT, Gordeuk VR, McLaren CE, Khumalo H, Saungweme T, Rouault T, Kiire CF. African iron overload and hepatocellular carcinoma (HA-7-0-080). Eur J Haematol 1998; 60: 28-34 [PMID: 9451425 DOI: 10.1111/j.1600-0609.1998.tb00993.x]
31. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 74-80 [PMID: 2295475 DOI: 10.1002/hep.1840110114]
32. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127: S35-S50 [PMID: 15508101 DOI: 10.1053/j.gastro.2004.09.014]
33. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-121 [PMID: 16012941 DOI: 10.1053/j.gastro.2005.04.014]
34. Shimada M, Hashimoto E, Taniai M, Hasegawa K, Okuda H, Hayashi N, Takasaki K, Ludwig J. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 2002; 37: 154-160 [PMID: 12076877 DOI: 10.1016/S0168-8278(02)00099-5]
35. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002; 36: 1349-1354 [PMID: 12447858]
36. Wolk A, Gridley G, Svensson M, Nyrén O, McLaughlin JK, Fraumeni JF, Adam HO. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 2001; 12: 13-21 [PMID: 11227921]
37. Polesel J, Zucchetto A, Montella M, Dal Maso L, Crispo A, La Vecchia C, Serraino D, Franceschi S, Talamini R. The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. Ann Oncol 2009; 20: 353-357 [PMID: 18723550 DOI: 10.1093/annonc/mdn565]
38. Moller H, Mellemgaard A, Lindvig K, Olsen JH. Obesity and cancer risk: a Danish record-linkage study. Eur J Cancer 1994; 30A: 344-350 [PMID: 8204357 DOI: 10.1016/0959-8049(94)90254-2]
39. Larsson SC, Wolk A. Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer 2007; 97: 1005-1008 [PMID: 17700568]
40. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 664-669 [PMID: 10051466 DOI: 10.1002/hep.510290347]
41. Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a casecontrol study. Hepatology 2000; 32: 689-692 [PMID: 11003611 DOI: 10.1053/jhep.2000.17894]
42. Noto H, Osame K, Sasazuki T, Noda M. Substantially increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis of epidemiologic evidence in Japan. J Diabetes Complications 2010; 24: 345-353 [PMID: 20656522 DOI: 10.1016/j.jdiacomp.2010.06.004]
43. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006; 4: 369-380 [PMID: 16527702 DOI: 10.1016/j.cgh.2005.12.007]
44. Polesel J, Talamini R, Montella M, Maso LD, Crovatto M, Parpinel M, Izzo F, Tommasi LG, Serraino D, La Vecchia C, Franceschi S. Nutrients intake and the risk of hepatocellular carcinoma in Italy. Eur J Cancer 2007; 43: 2381-2387 [PMID: 17719221 DOI: 10.1016/j.ejca.2007.07.012]
45. Talamini R, Polesel J, Montella M, Dal Maso L, Crispo A, Tommasi LG, Izzo F, Crovatto M, La Vecchia C, Franceschi S. Food groups and risk of hepatocellular carcinoma: A multicenter case-control study in Italy. Int J Cancer 2006; 119: 2916-2921 [PMID: 16998792 DOI: 10.1002/ijc.22267]
46. La Vecchia C, Negri E, Decarli A, D'Avanzo B, Franceschi S. Risk factors for hepatocellular carcinoma in northern Italy. Int J Cancer 1988; 42: 872-876 [PMID: 2847988 DOI: 10.1002/ijc.2910420614]
47. Sauvaget C, Nagano J, Hayashi M, Spencer E, Shimizu Y, Allen N. Vegetables and fruit intake and cancer mortality in the Hiroshima/Nagasaki Life Span Study. Br J Cancer 2003; 88: 689-694 [PMID: 12618875 DOI: 10.1038/sj.bjc.6600775]
48. Sarasua S, Savitz DA. Cured and broiled meat consumption in relation to childhood cancer: Denver, Colorado (United States). Cancer Causes Control 1994; 5: 141-148 [PMID: 8167261 DOI: 10.1007/BF01830260]
49. Lijinsky W. N-Nitroso compounds in the diet. Mutat Res 1999; 443: 129-138 [PMID: 10415436 DOI: 10.1016/S1383-5742(99)00015-0]
50. Ramanathan S, Kuppusamy A, Nallasamy VM, Perumal P. Antitumor effects and antioxidant role of Scutia myrtina in N-Nitroso-diethylamine (NDEA) induced hepatocellular carcinoma in rats. Asian J Pharm Biol Res 2011; 1: 71-78
51. Agency for Toxic Substances and Disease Registry. Toxicological profile for N nitrosodimethylamine. Atlanta, GA: US Department of Health and Human Services, 1989
52. Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A, Decarli A, Trevisi P, Ribero ML, Martelli C, Porru S, Nardi G. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002; 155: 323-331 [PMID: 11836196 DOI: 10.1093/aje/155.4.323]
53. Munaka M, Kohshi K, Kawamoto T, Takasawa S, Nagata N, Itoh H, Oda S, Katoh T. Genetic polymorphisms of tobaccoand alcohol-related metabolizing enzymes and the risk of hepatocellular carcinoma. J Cancer Res Clin Oncol 2003; 129: 355-360 [PMID: 12759747 DOI: 10.1007/s00432-003-0439-5]
54. Covolo L, Gelatti U, Talamini R, Garte S, Trevisi P, Franceschi S, Franceschini M, Barbone F, Tagger A, Ribero ML, Parrinello G, Donadon V, Nardi G, Donato F. Alcohol dehydrogenase 3, glutathione S-transferase M1 and T1 polymorphisms, alcohol consumption and hepatocellular carcinoma (Italy). Cancer Causes Control 2005; 16: 831-838 [PMID: 16132793 DOI: 10.1007/s10552-005-2302-2]
55. Marrero JA, Fontana RJ, Fu S, Conjeevaram HS, Su GL, Lok AS. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol 2005; 42: 218-224 [PMID: 15664247 DOI: 10.1016/j.jhep.2004.10.005]
56. Mizoue T, Tokui N, Nishisaka K, Nishisaka S, Ogimoto I, Ikeda M, Yoshimura T. Prospective study on the relation of cigarette smoking with cancer of the liver and stomach in an endemic region. Int J Epidemiol 2000; 29: 232-237 [PMID: 10817118 DOI: 10.1093/ije/29.2.232]
57. Yun YH, Jung KW, Bae JM, Lee JS, Shin SA, Min Park S, Yoo T, Yul Huh B. Cigarette smoking and cancer incidence risk in adult men: National Health Insurance Corporation Study. Cancer Detect Prev 2005; 29: 15-24 [PMID: 15734213 DOI: 10.1016/j.cdp.2004.08.006]
58. Zhu K, Moriarty C, Caplan LS, Levine RS. Cigarette smoking and primary liver cancer: a population-based case-control study in US men. Cancer Causes Control 2007; 18: 315-321 [PMID: 17294291 DOI: 10.1007/s10552-006-0105-8]
59. Jee SH, Ohrr H, Sull JW, Samet JM. Cigarette smoking, alcohol drinking, hepatitis B, and risk for hepatocellular carcinoma in Korea. J Natl Cancer Inst 2004; 96: 1851-1856 [PMID: 15601641 DOI: 10.1093/jnci/djh334]
60. Evans AA, Chen G, Ross EA, Shen FM, Lin WY, London WT. Eight-year follow-up of the 90,000-person Haimen City cohort: I. Hepatocellular carcinoma mortality, risk factors, and gender differences. Cancer Epidemiol Biomarkers Prev 2002; 11: 369-376 [PMID: 11927497]
61. Sun CA, Wu DM, Lin CC, Lu SN, You SL, Wang LY, Wu MH, Chen CJ. Incidence and cofactors of hepatitis C virusrelated hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. Am J Epidemiol 2003; 157: 674-682 [PMID: 12697571 DOI: 10.1093/aje/kwg041]
62. Tajada M, Nerín J, Ruiz MM, Sánchez-Dehesa M, Fabre E. Liver adenoma and focal nodular hyperplasia associated with oral contraceptives. Eur J Contracept Reprod Health Care 2001; 6: 227-230 [PMID: 11848652]
63. Rosenberg L. The risk of liver neoplasia in relation to combined oral contraceptive use. Contraception 1991; 43: 643-652 [PMID: 1651205 DOI: 10.1016/0010-7824(91)90007-3]
64. Korula J, Yellin A, Kanel G, Campofiori G, Nichols P. Hepatocellular carcinoma coexisting with hepatic adenoma. Incidental discovery after long-term oral contraceptive use. West J Med 1991; 155: 416-418 [PMID: 1663298]
65. Gordon SC, Reddy KR, Livingstone AS, Jeffers LJ, SchiffER. Resolution of a contraceptive-steroid-induced hepatic adenoma with subsequent evolution into hepatocellular carcinoma. Ann Intern Med 1986; 105: 547-549 [PMID: 3019201]
66. Ito M, Sasaki M, Wen CY, Nakashima M, Ueki T, Ishibashi H, Yano M, Kage M, Kojiro M. Liver cell adenoma with malignant transformation: a case report. World J Gastroenterol 2003; 9: 2379-2381 [PMID: 14562419]
67. Zucman-Rossi J, Jeannot E, Nhieu JT, Scoazec JY, Guettier C, Rebouissou S, Bacq Y, Leteurtre E, Paradis V, Michalak S, Wendum D, Chiche L, Fabre M, Mellottee L, Laurent C, Partensky C, Castaing D, Zafrani ES, Laurent-Puig P, Balabaud C, Bioulac-Sage P. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 2006; 43: 515-524 [PMID: 16496320 DOI: 10.1002/hep.21068]
68. Micchelli ST, Vivekanandan P, Boitnott JK, Pawlik TM, Choti MA, Torbenson M. Malignant transformation of hepatic adenomas. Mod Pathol 2008; 21: 491-497 [PMID: 18246041 DOI: 10.1038/modpathol.2008.8]
69. Maheshwari S, Sarraj A, Kramer J, El-Serag HB. Oral contraception and the risk of hepatocellular carcinoma. J Hepatol 2007; 47: 506-513 [PMID: 17462781 DOI: 10.1016/j.jhep.2007.03.015]
70. Tsai JF, Chuang LY, Jeng JE, Ho MS, Hsieh MY, Lin ZY, Wang LY. Betel quid chewing as a risk factor for hepatocellular carcinoma: a case-control study. Br J Cancer 2001; 84: 709-713 [PMID: 11237396 DOI: 10.1054/bjoc.1999.1597]
71. Jeng JH, Chang MC, Hahn LJ. Role of areca nut in betel quidassociated chemical carcinogenesis: current awareness and future perspectives. Oral Oncol 2001; 37: 477-492 [PMID: 11435174 DOI: 10.1016/S1368-8375(01)00003-3]
72. Tsai JF, Jeng JE, Chuang LY, Ho MS, Ko YC, Lin ZY, Hsieh MY, Chen SC, Chuang WL, Wang LY, Yu ML, Dai CY, Ho C. Habitual betel quid chewing as a risk factor for cirrhosis: a case-control study. Medicine (Baltimore) 2003; 82: 365-372 [PMID: 14530785 DOI: 10.1097/01.md.0000090401.56130.59]
73. Tsai JF, Jeng JE, Chuang LY, Ho MS, Ko YC, Lin ZY, Hsieh MY, Chen SC, Chuang WL, Wang LY, Yu ML, Dai CY. Habitual betel quid chewing and risk for hepatocellular carcinoma complicating cirrhosis. Medicine (Baltimore) 2004; 83: 176-187 [PMID: 15118544 DOI: 10.1097/01. md.0000126971.80227.a4]
74. Aguilar F, Hussain SP, Cerutti P. Aflatoxin B1 induces the transversion of G--& gt; T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc Natl Acad Sci USA 1993; 90: 8586-8590 [PMID: 8397412 DOI: 10.1073/pnas.90.18.8586]
75. Aguilar F, Harris CC, Sun T, Hollstein M, Cerutti P. Geographic variation of p53 mutational profile in nonmalignant human liver. Science 1994; 264: 1317-1319 [PMID: 8191284 DOI: 10.1126/science.8191284]
76. Zhang YJ, Rossner P, Chen Y, Agrawal M, Wang Q, Wang L, Ahsan H, Yu MW, Lee PH, Santella RM. Aflatoxin B1 and polycyclic aromatic hydrocarbon adducts, p53 mutations and p16 methylation in liver tissue and plasma of hepatocellular carcinoma patients. Int J Cancer 2006; 119: 985-991 [PMID: 16570275 DOI: 10.1002/ijc.21699]
77. Qian GS, Ross RK, Yu MC, Yuan JM, Gao YT, Henderson BE, Wogan GN, Groopman JD. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomarkers Prev 1994; 3: 3-10 [PMID: 8118382]
78. Dilber MS, Phelan A, Aints A, Mohamed AJ, Elliott G, Smith CI, O'Hare P. Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22. Gene Ther 1999; 6: 12-21 [PMID: 10341871]
79. Hifnawy MS, Mangoud AM, Eissa MH, Nor Edin E, Mostafa Y, Abouel-Magd Y, Sabee EI, Amin I, Ismail A, Morsy TA, Mahrous S, Afefy AF, el-Shorbagy E, el-Sadawy M, Ragab H, Hassan MI, el-Hady G, Saber M. The role of aflatoxin-contaminated food materials and HCV in developing hepatocellular carcinoma in Al-Sharkia Governorate, Egypt. J Egypt Soc Parasitol 2004; 34: 479-488 [PMID: 15124754]
80. Chen CJ, Wang LY, Lu SN, Wu MH, You SL, Zhang YJ, Wang LW, Santella RM. Elevated aflatoxin exposure and increased risk of hepatocellular carcinoma. Hepatology 1996; 24: 38-42 [PMID: 8707279 DOI: 10.1002/hep.510240108]
81. La Vecchia C, Tavani A. Coffee and cancer risk: an update. Eur J Cancer Prev 2007; 16: 385-389 [PMID: 17923807 DOI: 10.1097/01.cej.0000243853.12728.76]
82. Kono S, Shinchi K, Imanishi K, Todoroki I, Hatsuse K. Coffee and serum gamma-glutamyltransferase: a study of selfdefense officials in Japan. Am J Epidemiol 1994; 139: 723-727 [PMID: 7909403]
83. Gallus S, Bertuzzi M, Tavani A, Bosetti C, Negri E, La Vecchia C, Lagiou P, Trichopoulos D. Does coffee protect against hepatocellular carcinoma. Br J Cancer 2002; 87: 956-959 [PMID: 12434283 DOI: 10.1038/sj.bjc.6600582]
84. Shimazu T, Tsubono Y, Kuriyama S, Ohmori K, Koizumi Y, Nishino Y, Shibuya D, Tsuji I. Coffee consumption and the risk of primary liver cancer: pooled analysis of two prospective studies in Japan. Int J Cancer 2005; 116: 150-154 [PMID: 15756689 DOI: 10.1002/ijc.20989]
85. Bravi F, Bosetti C, Tavani A, Bagnardi V, Gallus S, Negri E, Franceschi S, La Vecchia C. Coffee drinking and hepatocellular carcinoma risk: a meta-analysis. Hepatology 2007; 46: 430-435 [PMID: 17580359 DOI: 10.1002/hep.21708]
86. Chou YH, Chiou HJ, Tiu CM, Chiou SY, Lee SD, Hung GS, Wu SC, Kuo BI, Lee RC, Chiang JH, Chang T, Yu C. Duplex Doppler ultrasound of hepatic Schistosomiasis japonica: a study of 47 patients. Am J Trop Med Hyg 2003; 68: 18-23 [PMID: 12556142]
87. Ezzat S, Abdel-Hamid M, Eissa SA, Mokhtar N, Labib NA, El-Ghorory L, Mikhail NN, Abdel-Hamid A, Hifnawy T, Strickland GT, Loffredo CA. Associations of pesticides, HCV, HBV, and hepatocellular carcinoma in Egypt. Int J Hyg Environ Health 2005; 208: 329-339 [PMID: 16217918 DOI: 10.1016/j.ijheh.2005.04.003]
88. McGlynn KA, London WT. Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2005; 19: 3-23 [PMID: 15757802 DOI: 10.1016/j.bpg.2004.10.004]
89. Bull LN, Carlton VE, Stricker NL, Baharloo S, DeYoung JA, Freimer NB, Magid MS, Kahn E, Markowitz J, DiCarlo FJ, McLoughlin L, Boyle JT, Dahms BB, Faught PR, Fitzgerald JF, Piccoli DA, Witzleben CL, O'Connell NC, Setchell KD, Agostini RM, Kocoshis SA, Reyes J, Knisely AS. Genetic and morphological findings in progressive familial intrahepatic cholestasis (Byler disease [PFIC-1] and Byler syndrome): evidence for heterogeneity. Hepatology 1997; 26: 155-164 [PMID: 9214465 DOI: 10.1002/hep.510260121]
90. Van Thiel DH, Ramadori G. Non-viral causes of hepatocellular carcinoma. J Gastrointest Cancer 2011; 42: 191-194 [PMID: 20820946 DOI: 10.1007/s12029-010-9195-3]
91. Bogdanos DP, Invernizzi P, Mackay IR, Vergani D. Autoimmune liver serology: current diagnostic and clinical challenges. World J Gastroenterol 2008; 14: 3374-3387 [PMID: 18528935 DOI: 10.3748/wjg.14.3374]
92. Wong RJ, Gish R, Frederick T, Bzowej N, Frenette C. Development of hepatocellular carcinoma in autoimmune hepatitis patients: a case series. Dig Dis Sci 2011; 56: 578-585 [PMID: 21046244 DOI: 10.1007/s10620-010-1444-6]
93. Dawn BM, Todd S, Kim SI, Glucksman M. Biochemistry and molecular biology. Philadelphia: Wolters Kluwer Health/Lippincott Williams and Wilkins, 2007
94. Mustajoki P. Acute intermittent porphyria. Semin Dermatol 1986; 5: 155
95. Lithner F, Wetterberg L. Hepatocellular carcinoma in patients with acute intermittent porphyria. Acta Med Scand 1984; 215: 271-274 [PMID: 6328897 DOI: 10.1111/j.0954-6820.1984. tb05005.x]
96. Mogl MT, Pascher A, Presser SJ, Schwabe M, Neuhaus P, Nuessler NC. An unhappy triad: hemochromatosis, porphyria cutanea tarda and hepatocellular carcinoma-a case report. World J Gastroenterol 2007; 13: 1998-2001 [PMID: 17461505]
97. Das SK, Ray K. Wilson's disease: an update. Nat Clin Pract Neurol 2006; 2: 482-493 [PMID: 16932613 DOI: 10.1038/ncpneuro0291] 98 Reyes CV. Hepatocellular carcinoma in Wilson Disease-related liver cirrhosis. Gastroenterol Hepatol (N Y) 2008; 4: 435-437
98. Reyes CV. Hepatocellular carcinoma in Wilson Disease-related liver cirrhosis. Gastroenterol Hepatol (N Y) 2008; 4: 435-437
99. Guan R, Oon CJ, Wong PK, Foong WC, Wee A. Primary hepatocellular carcinoma associated with Wilson's disease in a young woman. Postgrad Med J 1985; 61: 357-359 [PMID: 2991870 DOI: 10.1136/pgmj.61.714.357]
100. Liang Y, Yang Z, Zhong R. Primary biliary cirrhosis and cancer risk: a systematic review and meta-analysis. Hepatology 2012; 56: 1409-1417 [PMID: 22504852 DOI: 10.1002/hep.25788]
101. Harada K, Hirohara J, Ueno Y, Nakano T, Kakuda Y, Tsubouchi H, Ichida T, Nakanuma Y. Incidence of and risk factors for hepatocellular carcinoma in primary biliary cirrhosis: National data from Japan. Hepatology 2013; 57: 1942-1949 [PMID: 23197466 DOI: 10.1002/hep.26176]
102. Muguti G, Tait N, Richardson A, Little JM. Hepatic focal nodular hyperplasia: a benign incidentaloma or a marker of serious hepatic disease. HPB Surg 1992; 5: 171-176; discussion 176-180 [PMID: 1324705 DOI: 10.1155/1992/25139]
103. Turati F, Edefonti V, Talamini R, Ferraroni M, Malvezzi M, Bravi F, Franceschi S, Montella M, Polesel J, Zucchetto A, La Vecchia C, Negri E, Decarli A. Family history of liver cancer and hepatocellular carcinoma. Hepatology 2012; 55: 1416-1425 [PMID: 22095619 DOI: 10.1002/hep.24794]